Mylan is one of the world's leading global pharmaceutical companies with significant and growing presence. We have around 35,000 people, half of which are in India. Our wide portfolio includes a variety of dosage forms, generic and brand name products, which are sold in more than 165 countries and provinces.
Mylan's business in India began in 2007 with the acquisition of Matrix Laboratories Limited. The agreement has enabled Mylan to convert the night's active pharmaceutical ingredients (APIs) to the world's largest producers and allow our full dose form (FDF) to delay the preparation of medicines.
Today Mylan has 47 facilities in the production platform, of which 21 are in India. These facilities include all 9 Mylan's APIs and 12 full dosage facilities, which create high-quality medicines for emerging markets including worldwide markets. Among our therapeutic classes in our manufacturing capabilities in India, dosage form like tablets, capsules and injections are included.
HIV to third parties in the world Our business business in the Indian market for antroviral products living with AIDS / Integrated Quality API Today, 40% of 21 million HIV-positive patients have been diagnosed with therapeutic treatment due to the disease, all of which have been created in India. In addition, Mylan is the third largest drug exporter in India and we have a growing commercial presence in our existing portfolio, where our current portfolio includes Critical Care, Hepeta Care, HIV Care, Onco Care and Franchises in Women Care.
Besides, our presence in India is much more than the creation, sale and marketing. One of Hyderabad's two world R & D centers in Hyderabad is Hyderabad. There is a great deal of experience with the Center working with multiple authorities, from multiple countries. The company is fully integrated with the world R & D function, 'Unique and efficient,' development discovery, development, diagnostic and regulatory ability.
Join WhatsApp
Join Telegram
